I
N THE EARLY TRIALS of liver transplantation, an unequivocal indication for liver replacement was thought to be a primary hepatic malignancy that could not be removed by conventional techniques of subtotal hepatic resection. Enthusiasm for the approach was dampened in several major centers by the high recurrence rates of original malignancies. I -4 Nevertheless, the impulse to treat malignant tumors by liver transplantation is still present today because of: (1) the lack of other effective therapy; (2) rare examples of cure of malignancy by total hepatectomy and liver replacement; and (3) the improved overall survival after liver transplantation with cyclosporine-steroid therapy in recent years. The patient identification number (OT), age, sex, diagnosis, survival as of April 15, 1985 , tumor recurrence, and main cause of death for all patients are listed in Tables  1 and 2 . The recipient ages ranged from 2 to 68 years (mean: 30). There are 22 males and 32 females. There were 37 hepatocellular carcinomas (HCC), of which seven were the fibrolamellar variant. The other tumors were eight bile duct carcinomas (Klatskin tumors), three epitheloid hemangioendothelial sarcomas, two cholangiocarcinomas, and one each hepatoblastoma, angiosarcoma, adenocarcinoma of unknown primary site, and sarcoma of undetermined cell type (Table 3) .
Results

Residual Tumor
No patients with primary liver malignancy who underwent liver transplantation were known preoperatively to have extrahepatic involvement. However, three patients of Group II (OT 114,305, and 473) were left with gross residual neoplasm at the time of transplantation. One (OT 114) with sarcoma of undetermined cell type had fine metastases to the lung and peritoneum. She is still alive and well without any signs of tumor regrowth more than 8 years later. Another woman (OT 305) with hemangiosarcoma had metastases to the lungs and omentum at the time of transplantation. When she died 3 months after operation as the result of pneumonia and liver graft failure, her autopsy also revealed metastases to the bone marrow. The third patient (OT 473) had adenocarcinoma of unknown primary site with metastases to abdominal lymph nodes at the time of transplantation. This patient is alive and well without any clinical and radiological evidence of tumor enlargement or further metastasis in the fifth post-transplant month.
Eleven other patients in Group II (OT 2,3,4,5,6, 17, 25,79, 185,234,251) died within 2 months from various complications of liver transplantation. Before operation, all 11 were thought to be free of extrahepatic tumor. At autopsy, only one patient (OT 4) had gross or histopathologic evidence of residual neoplasm. This patient, who survived only 5 days after liver transplantation, had metastatic cholangiocarcinoma in the lungs, vertebra, kidneys, and some abdominal lymph nodes. The remaining 10 patients were tumor free insofar as this could be determined from complete post-mortem examination, indicating that screening for candidacy had been grossly accurate in the great majority of cases.
Tumor Recurrence
With incidental malignancies, In Group I, 12 of the 13 patients whose excised livers contained incidental primary liver malignancies are still alive and well without evidence of tumor recurrence after 4 months to more than 15 years (median: 16 months) ( found at transplantation to have extrahepatic involveare projected at 68% and 25% (Fig. 2) . At t~e. prese?t ment, as described in the preceding section. The other 27 time, only 10 (48%) of the original 21 recIpIents m (Table 4) were considered to have all gross tumor removed Subgroup B are still alive after 4 months to 3% years. One of the survivors (at 4 months) is a patient who had tumor by total hepatectomy. f I In 20 (74%) of the 27 patients who were made potenpositive regional lymph nodes at the time 0 transp antially tumor free by transplantation, the original tumor tation, and four others are living with known recurrences. recurred after 1 to 42 months (median: 8 months). Nonfibrolamellar hepatocellular carcinoma recurred in nine (82%) of 11 patients, all within a year (median: 4 months) ( Table 4) . Recurrence offibrolamellar hepatocellular carcinoma also was seen in four (57%) of seven patients (Table 4) but always after 1 year (median: 15 months). Four of the five bile duct carcinomas recurred, two before and two after the I-year mark; the exceptional patient who did not have a recurrence died of other causes only 2 months after the operation. Two of the three epitheloid hemangioendothelial sarcomas recurred within a year. One patient with cholangiocarcinoma developed a tumor recurrence in the 15th postoperative month.
Patient Survival
The overall results after liver transplantation have improved greatly since the introduction of cyclosporine-steroid therapy in March 1980. 5 Since this time, the survival expectation at 1 postoperative year and each year thereafter for at least 5 years has more than doubled compared to that previously obtained with azathioprine, prednisone, and ALG (Fig. 1) . The projected actuarial 5-year survival in all patients treated since 1980 is 63%.
Group I tumor patients. Twelve of the 13 patients who had incidental hepatic malignancies are still alive from 4 months to 15 1 12 years after surgery ( Table 1 ). The only mortality was of a patient treated with azathioprine, prednisone, and ALG (Subgroup A), who died on the first postoperative day. The two other patients of Subgroup A, as well as all 10 of the recipients treated with cyclosporine and steroids (Subgroup B), are living (Table 1) .
Group II tumor patients. Of the 20 patients of Subgroup A who were treated with azathioprine, prednisone, and ALG, 13 (65%) had died by the end of the first 6 months. At the end of the year, only 6 (30%) remained alive, of whom all but one have subsequently died (Fig. 2) . The single survivor, now 8% years after surgery, had a sarcoma of undetermined cell type with peritoneal and pulmonary metastases at the time of transplantation.
The patients of Subgroup B had greatly improved early postoperative results, with a 6-month actuarial survival of more than 80%. This reflected the better overall prognosis for early recovery using cyclosporine-steroid therapy. However, after the half-year mark, survival continued to decline, primarily because of the recurrent disease, as will be described in the next two sections. The actuarial land 3-year survivals in the cyclosporine-treated patients
Main Causes oJGroup II Patient Deaths
Thirty of the 41 patients whose principal reason for liver transplantation was the presence of a primary liver malignancy had died before April 15, 1985 . Twenty-one of the 30 deaths were within 1 year after transplantation, and five of the 21 deaths were directly caused 5 to 12 months after transplantation by tumor recurrence. The rest of the deaths during the first year were due to nonneoplastic complications such as graft failure or infections, or both (Table 2) ; the majority of these cases were from our early experience before 1970. Of the nine deaths that occurred a year or more after transplantation, eight were caused directly by tumor recurrence (Table 2) . Thus, the shape of the life survival curves both before and after the introduction of cyc1osporine was dominated from the fifth month onward by the deadly effects of tumor recurrence.
Histology versus Survival in 41 Group II Patients
Of the seven patients with fibrolamellar hepatocellular carcinoma, one, who is free of tumor after 5 months, has too short a follow-up to merit comment. The other six lived for at least 1 year and were thought to be free of tumor at the end of that time. Subsequently, metastases developed in four of the six recipients, of whom two died. The two patients who are living with known recurrent fibrolamellar neoplasms have been followed for 17 and 36 months, and one has seemed to respond to adriamycin and other chemotherapeutic agents.
In contrast, patients with nonfibrolamellar hepatocellular carcinomas had earlier and more lethal metastases. Of 25 such recipients, two who are alive after 5 and 6 months have too short a follow-up to be discussed. Of the other 23, five lived for as long as 1 year, at which time all but one had known metastases. The four who had metastases at 1 year died 12 to 17 months after transplantation; the fifth patient remains tumor free after 15 months. Thus, the conventional hepatomas carried a far poorer prognosis than the fibrolamellar variant.
Of the 16 patients with malignancies other than hepatocellular carcinoma, six lived more than 1 year, and one (OT 473) is alive in the fourth month (Table 4) .
Location oj Recurrences
The grafted liver and the lung were the two organs most commonly affected by tumor recurrence ( liver was ultimately involved by recurrent tumor in 12 later developed metastases. The liver was the first site of cases. Other locations within the abdomen such as abrecurrence in eight cases, the lung in six cases, both the dominallymph nodes and the peritoneum were affected liver and the lung simultaneously in two cases, the bone in 13 cases. The lung became involved in 11 cases, and in two cases, and the skin and the pelvic peritoneum in the brain and the bones in three cases each.
one case each. The first locations of tumor recurrence and the organs ultimately involved by tumors were examined in the 20 Discussion patients of Group II (Table 2) otherwise diseased livers also contained incidental hepatomas or, in one instance, a hepatoblastoma. The fact that none of these patients developed a recurrence during the 4 months to 15 1 1z years of follow-up proved that the mere presence of a hepatic malignancy is not an absolute contraindication to transplantation. Nevertheless, there was a tumor recurrence rate of74% in the patients of Group II who had neoplasms that were the fundamental reason for the total hepatectomy and transplantation and who survived for at least 2 months. It is possible that the high recurrence rate in Group II recipients merely reflected the advanced development of the neoplasms by the time a decision was made to attempt therapy with transplantation. An alternative and not necessarily mutually exclusive explanation is that the immunosuppression necessary to prevent graft rejection may actually have expedited the growth of residual nests of cells left after the total hepatectomy, as was suggested a number of years ago l and supported by many recent investigations host factors promoting metastases. 6 -8 The tendency of the metastases from hepatic malignancies to come back to the liver grafts has been noted before. 1, 2 Of all the tumor types for which experience has been accumulated so far, the fibrolamellar hepatocellular carcinoma has emerged as the best for treatment with trans- plantation, This hepatoma variant, which was originally recognized by Edmondson 9 and Peters, IO is known to behave less aggressively than most other malignant hepatic neoplasms, including the more common kind of hepatocellular carcinoma. I 1-13 Although four of our seven patients with fibrolamellar hepatomas developed metastases, these tended to appear late and to grow relatively slowly. One of our patients with recurrence is in very good health 2 years after multiple pulmonary metastases were first proved.
With all other kinds of tumors, including the rest of the hepatocellular carcinomas, metastases have tended to appear early and to lead to death promptly. The prognosis with conventional hepatocellular carcinomas has been grim. Similarly, none of our patients with proximal duct cell carcinomas (Klatskin tumors) has been "cured," and, to our knowledge, this has not been accomplished in any other center.
It has been tempting during the acquisition of this experience to conclude that liver replacement for malignant hepatic neoplasms is conceptually unsound, except for fibrolamellar hepatomas, and to abandon such efforts. However, arrest and control of the malignant process have been accomplished under some ofthe least likely circumstances, as with the woman who had pulmonary and peritoneal seeding from a sarcoma at the time of transplantation, the recipient with epitheloid hemangioendothelial sarcoma, and the patient with a conventional hepatoma. There has been no identifiable reason why the patients were spared recurrence and why the others were not.
Liver transplantation will have to be tied to some other kind of therapeutic effort in future trials. The usual approach of giving adjuvant chemotherapy will not be good enough, as was shown in two of our recent patients with nonfibrolamellar hepatocellular carcinomas who developed metastases within a few months in spite of very aggressive prophylactic treatment with adriamycin and other chemotherapeutic agents. Huber et al. 14 have described a novel approach in which two patients with metastatic liver disease had liver replacement as well as total body irradiation, chemotherapy, and bone marrow transplantation. One of their recipients whose original disease was a carcinoma of the breast was alive 3 years later after liver replacement and was free of tumor. I 5 DR. JAMES H. FOSTER (Farmington, Connecticut): Dr. Iwatsuki, can you telI us anything about liver transplantation for secondary or metastatic cancer? DR. SHUNZABURO IWATSUKI (Closing discussion): Thank you very much, Dr. Russell. To answer your question as to how to select the patients, the way we usually handle the cancer patient for transplant is that we set up liver transplantation for two patients; the first patient, who is known to have a malignancy, and the second patient, who is known to have a benign disease. We start the operation earlier than the usual time and explore the cancer patient first. If the patient has extrahepatic involvement of the tumor, we stop the procedure there and call for the second patient.
Answering the question of Dr. O'Leary, as I mentioned briefly during the presentation, we have tried chemotherapy after transplant before the recurrence. Adriamycin® was used in a pretty heavy dose in a short period of time for a few patients with hepatomas. Two patients who had hepatoma suffered a recurrence within 3 months in spite of the chemotherapy. Therefore, we need more effective chemotherapeutic agents, or something else has to be added to liver replacement.
Answering the question of Dr. Foster, we have not done any transplantation for the patient with secondary metastasis. The Cambridge group and the Hanover group tried in several patients with metastatic liver malignancy, and they all died in 1 year with aggressive metastasis.
Answering the question of whether the liver tumor after transplant is actually a recurrence or a de novo tumor, we do not know it for sure, but histologic characteristics of the recurrent tumor were quite similar to the original tumor that the recipient had before transplant, and there was almost always extrahepatic involvement by the time liver tumor was c1inicalIy detected.
